Lazard Asset Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $1.41M | Buy |
21,704
+489
| +2% | +$35.6K | ﹤0.01% | 1086 |
|
|
2026
Q2 | $1.73M | Sell |
21,215
-4,773
| -18% | -$345K | ﹤0.01% | 1051 |
|
|
2026
Q1 | $1.77M | Buy |
25,988
+2,788
| +12% | +$197K | ﹤0.01% | 955 |
|
|
2025
Q4 | $1.76M | Buy |
23,200
+4,255
| +22% | +$309K | ﹤0.01% | 921 |
|
|
2025
Q3 | $1.16M | Sell |
18,945
-2,881
| -13% | -$150K | ﹤0.01% | 1095 |
|
|
2025
Q2 | $1.06M | Sell |
21,826
-278
| -1% | -$13.2K | ﹤0.01% | 1281 |
|
|
2025
Q1 | $1.12M | Sell |
22,104
-23,543
| -52% | -$1.17M | ﹤0.01% | 1179 |
|
|
2024
Q4 | $2.06M | Buy |
45,647
+34,069
| +294% | +$1.46M | ﹤0.01% | 872 |
|
|
2024
Q3 | $428K | Sell |
11,578
-7,082
| -38% | -$237K | ﹤0.01% | 1405 |
|
|
2024
Q2 | $568K | Buy |
18,660
+12,156
| +187% | +$394K | ﹤0.01% | 1158 |
|
|
2024
Q1 | $188K | Buy |
6,504
+4,741
| +269% | +$133K | ﹤0.01% | 1317 |
|
|
2023
Q4 | $47K | Sell |
1,763
-3,637
| -67% | -$83.2K | ﹤0.01% | 1904 |
|
|
2023
Q3 | $120K | Buy |
5,400
+1,063
| +25% | +$39.5K | ﹤0.01% | 1562 |
|
|
2023
Q2 | $175K | Buy |
4,337
+3,017
| +229% | +$148K | ﹤0.01% | 1383 |
|
|
2023
Q1 | $63K | Sell |
1,320
-1,158
| -47% | -$52.9K | ﹤0.01% | 1722 |
|
|
2022
Q4 | $94K | Buy |
2,478
+1,326
| +115% | +$55.1K | ﹤0.01% | 1554 |
|
|
2022
Q3 | $57K | Buy |
+1,152
| New | +$56.4K | ﹤0.01% | 1741 |
|
|
2022
Q2 | – | Sell |
-25,192
| Closed | -$939K | – | 2537 |
|
|
2022
Q1 | $939K | Buy |
25,192
+23,250
| +1,197% | +$896K | ﹤0.01% | 1009 |
|
|
2021
Q4 | $77K | Buy |
+1,942
| New | +$74.3K | ﹤0.01% | 1543 |
|
|
2021
Q3 | – | Sell |
-282
| Closed | -$11K | – | 2261 |
|
|
2021
Q2 | $11K | Sell |
282
-2,931
| -91% | -$126K | ﹤0.01% | 1895 |
|
|
2021
Q1 | $152K | Sell |
3,213
-6,821
| -68% | -$405K | ﹤0.01% | 1143 |
|
|
2020
Q4 | $612K | Buy |
+10,034
| New | +$591K | ﹤0.01% | 950 |
|
|
2020
Q2 | – | Sell |
-1,580
| Closed | -$70K | – | 1757 |
|
|
2020
Q1 | $70K | Buy |
+1,580
| New | +$79.6K | ﹤0.01% | 1081 |
|
|
2019
Q4 | – | Sell |
-346
| Closed | -$11K | – | 1639 |
|
|
2019
Q3 | $11K | Buy |
+346
| New | +$15.1K | ﹤0.01% | 1294 |
|
|
2016
Q1 | – | Sell |
-9,275
| Closed | -$300K | – | 1094 |
|
|
2015
Q4 | $300K | Sell |
9,275
-6,234
| -40% | -$183K | ﹤0.01% | 769 |
|
|
2015
Q3 | $414K | Buy |
+15,509
| New | +$663K | ﹤0.01% | 718 |
|
Other funds holding PTCT
Lazard Asset Management's PTCT Position: Q3 2026 in Review
Lazard Asset Management increased its PTC Therapeutics (PTCT) stake by 2.3% in Q3 2026, buying an estimated $35.6K and bringing the position to 21,704 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1086.
Lazard Asset Management first reported a position in PTCT in Q3 2015 and has held it in 26 quarters since. The position peaked at $2.06M in Q4 2024. 361 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.
- Lazard Asset Management held 21,704 shares of PTC Therapeutics worth $1.41M as of Q3 2026.
- Lazard Asset Management bought 489 PTC Therapeutics shares in Q3 2026, an estimated $35.6K.
- PTC Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #1086 holding.
- Lazard Asset Management first reported a position in PTC Therapeutics in Q3 2015 and has held it in 26 quarters since.
- Lazard Asset Management's PTC Therapeutics position peaked at $2.06M in Q4 2024.
- 361 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.
Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.